SCHEMBL3557022

SCHEMBL3557022

O=C(O)[C@H](OC(O)c1ccccc1)[C@@H](OC(O)c1ccccc1)C(=O)O

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 2/20 0.54
LMNA P02545 3/20 0.52
MAPK1 P28482 1/20 0.52
SRC P12931 2/20 0.48
KMT2A Q03164 2/20 0.45
TP53 P04637 1/20 0.45
TSHR P16473 1/20 0.45
CES2 O00748 2/20 0.42
CES1 P23141 2/20 0.42
L3MBTL1 Q9Y468 2/20 0.39
KDM4E B2RXH2 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
HPGD P15428 1/20 0.38
MEN1 O00255 1/20 0.38
CYP1A2 P05177 1/20 0.38
CYP2C9 P11712 1/20 0.38
CYP2C19 P33261 1/20 0.38
SLC1A3 P43003 1/20 0.38
SLC1A2 P43004 1/20 0.38
SLC1A1 P43005 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13551473 1.00 CYP2D6 (0.54) CYP2D6LMNAMAPK1SRCKMT2A
SCHEMBL3563014 0.87 CYP2D6 (0.45) CYP2D6LMNAMAPK1SRCKMT2A
SCHEMBL25666223 0.86 TSHR (0.71) CYP2D6LMNAMAPK1KMT2ATP53
SCHEMBL25666225 0.86 TSHR (0.71) CYP2D6LMNAMAPK1KMT2ATP53
SCHEMBL1094149 0.81 LMNA (0.46) CYP2D6LMNAMAPK1SRCTSHR
SCHEMBL28262203 0.80 CYP2D6 (0.56) CYP2D6LMNAMAPK1SRCKMT2A
SCHEMBL13574482 0.75 GABBR2 (0.44) CYP2D6LMNAMAPK1SRCKMT2A
SCHEMBL27389870 0.73 LMNA (0.39) CYP2D6LMNAMAPK1SRCKMT2A
SCHEMBL7940904 0.72 CYP2D6 (0.52) CYP2D6LMNAMAPK1SRCKMT2A
SCHEMBL7940900 0.72 CYP2D6 (0.52) CYP2D6LMNAMAPK1SRCKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8158796-B2 Process for the preparation of Rho-kinase inhibitor compounds INSPIRE PHARMACEUTICALS, INC. (US) 2012-04-17 US disclosed
US-20100022775-A1 PROCESS FOR THE PREPARATION OF RHO-KINASE INHIBITOR COMPOUNDS INSPIRE PHARMACEUTICALS, INC. 2010-01-28 US disclosed
WO-2009154940-A1 PROCESS FOR THE PREPARATION OF RHO-KINASE INHIBITOR COMPOUNDS INSPIRE PHARMACEUTICALS, INC. (US) 2009-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100022775-A1 PROCESS FOR THE PREPARATION OF RHO-KINASE INHIBITOR COMPOUNDS ROCK1, ROCK2, RHOA CYP2D6 2375/4885LMNA 1563/4885MAPK1 178/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.